Cost-effectiveness of preimplantation genetic testing for aneuploidy for fresh donor oocyte cycles

Assisted Reproduction

Like Comment
Related Content

VOLUME 2, ISSUE 1, P36-42, MARCH 01, 2021


Maria Facadio Antero, M.D., Bhuchitra Singh, M.D., M.P.H, M.S., Apoorva Pradhan, B.A.M.S., M.P.H., Megan Gornet, M.D., William G. Kearns, Ph.D., Valerie Baker, M.D., M.P.P., Mindy S. Christianson, M.D.



To determine whether in vitro fertilization (IVF) with preimplantation genetic testing for aneuploidy (PGT-A) is cost effective to achieve a live birth compared with IVF alone in fresh donor oocyte cycles.


Theoretical cost-effectiveness study.


Not applicable.




Comparison between the cost of IVF with PGT-A vs. IVF alone to achieve a live birth. The model analyzed a hypothetical single fresh oocyte donor IVF cycle with PGT-A vs. IVF alone and followed the progression of a single embryo through the different decision nodes. Cost estimates assigned to each clinical event were based on data obtained from the literature and institutional costs.

Main Outcome Measure(s)

Cost per live birth.


In the base-case analysis, IVF with PGT-A was not cost effective in fresh donor oocyte cycles when compared with IVF alone to achieve a live birth. The cycles using PGT-A cost an additional $6,018.66. The incremental cost-effectiveness ratio was found to be $119,606.59 per additional live birth achieved with IVF with PGT-A. Monte Carlo simulations demonstrated that IVF with PGT-A was not cost effective in nearly all iterations.


PGT-A in fresh donor oocyte IVF cycles is not cost effective compared with IVF alone over a wide range of probabilities and costs.

Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders.